no weight loss with tirzepatide obesity trial non-diabetic pros and cons for A 72-week compared the two leading GLP-1 medications in adults (no diabetes). The Tirzepatide outcompetes long-acting insulin in – Tirzepatide vs. Semaglutide for Weight

Insurance coverage is actually higher than most people realize

Large-scale trials, including cardiovascular outcome studies, have not reported a significant rise in heart failure incidents among tirzepatide users

Back Carlsson, LMS, Carlsson, B, Jacobson, P, et al (12 July 2023) 'Life expectancy after bariatric surgery or usual care in patients with or without baseline type 2 diabetes in Swedish obese subjects', International Journal of Obesity (London) , 47/10

The GI side effects from both compounds are manageable for most people, but they can be severe enough to require dose reduction or treatment discontinuation in a meaningful minority

Your healthcare provider can determine which nutrients require monitoring based on your individual dietary intake and risk factors

Findings from Cell Experiments In the 2018 study, 5-Amino-1MQ was assessed for membrane permeability using a PAMPA assay, which gave a passive permeability of 3.01 10 6 cm/s